New treatment for advanced liver cancer using light-activated nanoparticles
Official title: Clinical Translation of Interstitial Chemophototherapy with Light-Activated Nanoparticulate Doxorubicin
Funded at Pop Biotechnologies, INC · NIH-10830696 · Data updated 2026-11-12
This study is testing a new treatment for people with advanced liver cancer that combines a special chemotherapy drug with laser light to help target the tumor more effectively and reduce side effects.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Pop Biotechnologies, INC NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $249,873 |
| NIH project number | 1SB1CA288098-01 |
| Project ID | NIH-10830696 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with locally advanced liver cancer who have not responded to standard treatments.
✕Less likely to help
Patients with early-stage liver cancer or those who do not have liver cancer may not benefit from this research.
What this research studies
This research investigates a novel therapy called interstitial chemo-phototherapy (I-CPT) for patients with locally advanced liver cancers. It utilizes a special formulation of doxorubicin, a chemotherapy drug, which is encapsulated in nanoparticles that can be activated by laser light. When the nanoparticles are exposed to a specific wavelength of light, they release the drug directly into the tumor, potentially leading to more effective treatment with fewer side effects. The research aims to optimize this treatment approach and gather necessary safety data to prepare for human clinical trials.
Why it matters
Potential benefit: If successful, this research could provide a more effective and targeted treatment option for patients with advanced liver cancer.
How similar studies have gone: Previous studies have shown promise in using light-activated therapies for cancer treatment, indicating potential success for this novel approach.
Where this research is happening
-
Pop Biotechnologies, INC
Buffalo, United States Active
Researchers
- Principal investigator: Kutscher, Hilliard — Pop Biotechnologies, INC
- Study coordinator: Kutscher, Hilliard
Related research
Other NIH-funded projects on the same topics.
-
Multivalent tau and Aβ vaccine on SNAP liposomes for Alzheimer’s disease
A new vaccine approach aims to train the immune system to target multiple Alzheimer’s disease proteins at once, potentially slowing or preventing progression in people at risk.
-
A targeted immune therapy against artery disease using a liposome-linked ApoB fragment
A first-in-class approach aims to train the immune system to fight atherosclerosis by using a tiny ApoB fragment displayed on a liposome to elicit a protective immune response.
-
Advanced mosaic influenza vaccine platform to protect people faster and with fewer doses
A new vaccine approach uses a nanoparticle platform to deliver multiple flu antigens together, aiming to provide strong protection with smaller doses and quicker deployment.
-
Vaccine that targets several amyloid (Aβ) and tau pieces for Alzheimer's
This project is making a vaccine that trains the immune system to target both amyloid and tau proteins to help people at risk for or living with Alzheimer's disease.
-
Peptide vaccine to prevent serious Candida bloodstream infections, including drug‑resistant C. auris
This project develops a liposome-based peptide vaccine intended to help protect hospitalized and immunocompromised people from life-threatening Candida bloodstream infections, including drug‑resistant C. auris.
-
Testing a new influenza vaccine that uses less antigen and can be deployed quickly.
This study is testing a new type of flu vaccine that uses tiny particles to boost your immune response, so you can get better protection against different flu strains with smaller doses, making it easier to use during outbreaks.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.